Teva Pharmaceutical Industries (NYSE:TEVA) Shares Up 2.5% – Still a Buy?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was up 2.5% on Monday . The company traded as high as $15.48 and last traded at $15.46. Approximately 5,546,124 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 9,641,032 shares. The stock had previously closed at $15.08.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TEVA shares. StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Barclays cut their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Bank of America lowered their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Finally, Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a fifty day moving average of $17.21 and a two-hundred day moving average of $18.12. The stock has a market capitalization of $17.47 billion, a P/E ratio of -10.66, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Large investors have recently bought and sold shares of the stock. Stifel Financial Corp increased its position in shares of Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after purchasing an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after acquiring an additional 33,277 shares during the period. Pinnbrook Capital Management LP acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $4,966,000. Asset Management One Co. Ltd. increased its stake in Teva Pharmaceutical Industries by 14.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock valued at $10,414,000 after acquiring an additional 58,413 shares during the period. Finally, CWA Asset Management Group LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $3,340,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.